The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK) been one of those stocks this year? By taking ...

McKesson’s MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson’s strategic ...

McKesson Co. (NYSE:MCK – Get Free Report)’s share price rose 1.4% on Friday after Mizuho raised their price target on the stock from $630.00 to $690.00. Mizuho currently has a neutral rating on the ...

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.